

Clinical test report - Illustrative example

Hedera Profiling 2 ctDNA test panel (HP2)




Report LOC-5834-8470 on 26 September 2023 at 15:15 (UTC+03:00)



Patient		Order		Sample	
ID	89238923	Test	HP2	Sample ID	A123456
Name	John Johnsson	Organisation	Saidé Genomics	Sample type	Whole blood
Date of Birth	05 March 1958	Assigned clinician	Christie McKenzie		
Sex	Male				
Cancer type	Lung Cancer (NSCLC)				



Summary of findings and conclusions

Summary of findings can be added here...



Variants and therapies

Gene	cDNA change	Protein change	VAF %	Lab classification	Reference classifications
BRAF	c.1799T>A	V600E <i>p. (Val600Glu)</i>	0.97	Pathogenic	ClinVar Pathogenic ID: 13961 OncoKB Oncogenic
Related therapy options					
Therapy	EMA Approval			FDA Approval (OncoKB levels of evidence)	
Dabrafenib & Trametinib	 Effective	Lung Cancer (NSCLC), Melanoma		 L1 - FDA-recognized  L2 - Standard care	Non-Small Cell Lung Cancer, Thyroid Cancer, Melanoma Biliary Tract Cancer, Histiocytosis, Glioma

Fusion gene:exon	Confidence score %	Lab classification	Reference classifications
EML4:6 ALK:20	98.20	Pathogenic	OncoKB Oncogenic
Related therapy options			
Therapy	EMA Approval		FDA Approval (OncoKB levels of evidence)
Alectinib	 Effective	Lung Cancer (NSCLC)	 L1 - FDA-recognized Non-Small Cell Lung Cancer

CNV gene	CNV status	Transcript	Affected exons	Fold change
MET	Gain	NM_000245.4	5/21 <i>Exons: 1-4, 6</i>	3.2
Related therapy options				
Therapy	EMA Approval			FDA Approval (OncoKB levels of evidence)
Erlotinib, Gefitinib & Osimertinib	 Ineffective	Lung Cancer (NSCLC)	 R2 - Investigational Resistance	Non-Small Cell Lung Cancer

Mutational signatures

Microsatellite status	MSI-High	Confidence score %	98.10	Unstable loci	9/18
Related therapy options					
Therapy	EMA Approval			FDA Approval (OncoKB levels of evidence)	
Pembrolizumab	 Effective	CRC, Endometrial carcinoma, Gastric, Small intestine, Biliary cancer	 L1 - FDA-recognized	All solid tumors	

Sign off Report signed off by Oscar Oscarsson, on 26 September 2023 at 15:15 (UTC+03:00)

Performing laboratory Saidé Genomics

